24.09.2019 • NewsElaine BurridgemcdermottLummus Technology

McDermott Explores Lummus Technology Sale

McDermott Explores Lummus Technology Sale (c) McDermott
McDermott Explores Lummus Technology Sale (c) McDermott

Major engineering and construction company McDermott International is mulling a potential sale of its Lummus Technology arm after receiving unsolicited approaches exceeding $2.5 billion for all or part of the business.

The company has retained US investment bank Evercore as the lead advisor on a process that will “explore strategic alternatives to unlock the value of Lummus Technology while maintaining the strategic rationale of engineering, procurement and construction pull-through”.

McDermott did not reveal the names of the companies that have bid for Lummus, which is a leading licensor of proprietary technologies for petrochemicals, refining, gasification and gas processing and a supplier of proprietary catalysts and relating engineering, holding roughly 3,100 patents and patent applications.

“The process of exploring strategic alternatives is part of our ongoing efforts intended to improve McDermott's capital structure, and we plan to use the proceeds from any transaction involving Lummus Technology to strengthen our balance sheet,” said McDermott’s  president and CEO David Dickson. “While Lummus is an important business within McDermott, we have decided to undertake a process to fully realize its strategic and financial value.”

The Houston-based group inherited Lummus through its purchase of CB&I in May 2018. CBI had previously purchased Lummus from ABB for $950 million in November 2007.

The announcement has come after the Houston-based group announced poor second-quarter results and lowered its guidance for 2019 overall. Operating income plunged 52% year on year for the period April-June 2019 and McDermott is now anticipating a net loss of $310 million for the full year. The company is said to have hired turnaround consulting firm Alix Partners as an advisor to improve cash flow and stem the recent run of losses.

McDermott added that its previously announced processes to sell the remaining portion of its pipe fabrication business and its industrial storage tank business were ongoing.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.